natgillin/translations-raw huggingface dataset:
It is used in patients with ocular hypertension (when the pressure in the eye is higher than normal) or open-angle glaucoma (a disease in which the pressure inside the eye rises because fluid cannot drain out of the eye).
Uporablja se pri bolnikih z okularno hipertenzijo (kadar je tlak v očesu višji od običajnega) ali glavkomom odprtega zakotja (boleznijo, pri kateri se tlak v očesu zviša, ker tekočina ne more iztekati iz očesa).
In both studies, adding either Azopt or timolol caused a further decrease in eye pressure of around 3.5 mmHg after 12 weeks.
V obeh študijah je dodatek zdravila Azopt ali timolola povzročil dodatno znižanje tlaka v očesu za približno 3,5 mmHg po 12 tednih.
Azopt is used to reduce the pressure inside the eye.
Zdravilo Azopt se uporablja za zniževanje tlaka v očesu.
Azopt must not be used in people who are hypersensitive (allergic) to brinzolamide or any of the other ingredients, or to other medicines called sulphonamides (such as some antibiotics).
Zdravila Azopt ne smejo uporabljati osebe, ki so preobčutljive za (alergične na) brinzolamid ali katero koli drugo sestavino zdravila ali druga zdravila, imenovana sulfonamidi (kot so nekateri antibiotiki).
Overall, Azopt showed a similar effect when used two or three times a day.
Zdravilo Azopt je izkazalo podoben učinek, kadar so ga bolniki jemali dvakrat ali trikrat dnevno.
Bicarbonate is required for the production of the aqueous humour (the watery fluid in the eye).
Bikarbonat je potreben za proizvodnjo prekatne vodke (vodene tekočine v očesu).
Raised pressure inside the eye causes damage to the retina (the light-sensitive surface at the back of the eye) and to the optic nerve (the nerve that sends signals from the eye to the brain).
Zvišan tlak znotraj očesa poškoduje mrežnico (površino na zadnji strani zrkla, ki je občutljiva za svetlobo) in vidni živec (živec, ki pošilja signale iz očesa v možgane).
It is available as an eye drop suspension.
Na voljo je kot suspenzija v obliki kapljic za oko.
By blocking the production of bicarbonate in the eye, Azopt slows down the production of aqueous humour, reducing the pressure inside the eye.
Z zaviranjem proizvodnje bikarbonata v očesu zdravilo Azopt upočasni proizvodnjo prekatne vodke in tako zniža tlak v očesu.
Why has Azopt been approved?
Zakaj je bilo zdravilo Azopt odobreno?
It works by blocking an enzyme called carbonic anhydrase, which produces bicarbonate in the body.
Deluje tako, da zavira karboanahidrazo, encim, ki v telesu proizvaja bikarbonat.
When used on its own, Azopt was less effective than timolol.
Zdravilo Azopt, uporabljeno samostojno, je bilo manj učinkovito kot timolol.
Azopt caused a reduction in eye pressure of between 2.7 and 5.7 mmHg over 18 months, compared with a reduction of between 5.2 and 6.0 mmHg with timolol.
Zdravilo Azopt je v 18 mesecih povzročilo znižanje tlaka v očesu od 2,7 do 5,7 mmHg, timolol pa od 5,2 do 6,0 mmHg.
Azopt is used as an add-on to beta blockers or prostaglandin analogues (other medicines used for these conditions), or on its own in patients who cannot take or do not respond to beta blockers.
Zdravilo Azopt se uporablja kot dodatek zaviralcem beta receptorjev ali prostaglandinskim analogom (drugima zdraviloma za ti dve bolezni) ali samostojno pri bolnikih, ki ne prenašajo zaviralcev beta receptorjev ali se nanje ne odzivajo.
Two of the studies compared adding Azopt, dorzolamide or placebo (a dummy treatment) to timolol, and the final two studies compared Azopt used twice a day with timolol, when they were used as an add-on to travoprost (a prostaglandin analogue).
V dveh študijah so primerjali zdravilo Azopt, dorzolamid ali placebo (zdravilo brez zdravilne učinkovine) kot dodatek timololu, v zadnjih dveh študijah pa so primerjali zdravilo Azopt, ki so ga bolniki jemali dvakrat na dan, s timololom, kadar sta bila oba uporabljena kot dodatek travoprostu (prostaglandinskemu analogu).
Azopt is a medicine that contains the active substance brinzolamide.
Azopt je zdravilo, ki vsebuje zdravilno učinkovino brimzolamid.
The active substance in Azopt, brinzolamide, is a carbonic anhydrase inhibitor.
Zdravilna učinkovina zdravila Azopt, brinzolamid, je zaviralec karboanahidraze.
In three of the studies, Azopt, used on its own two or three times a day, was compared with timolol (a beta-blocker) and with dorzolamide (another carbonic anhydrase inhibitor).
V treh študijah so zdravilo Azopt, ki so ga bolniki jemali samostojno z dvema ali tremi odmerki na dan, primerjali s timololom (zaviralcem beta receptorjev) in dorzolamidom (drugim zaviralcem karboanahidraze).
Azopt was as effective as dorzolamide when used on its own or as an add-on to timolol, with decreases in pressure of between 3.4 and 5.7 mmHg.
Zdravilo Azopt je bilo samostojno ali v kombinaciji s timololom enako učinkovito kot dorzolamid; tlak v očesu se je znižal od 3,4 do 5,7 mmHg.
Azopt was also more effective than placebo when used as an add-on to timolol.
Zdravilo Azopt je bilo kot dodatek timololu učinkovitejše tudi od placeba.
The most common side effects with Azopt (seen in more than 1 patient in 20) are dysgeusia (a bitter or unusual taste in the mouth) and temporary blurring of vision.
Najpogostejša neželena učinka zdravila Azopt (opažena pri več kot 1 bolniku od 20) sta disgevzija (trpek ali nenavaden okus v ustih) in začasno zamegljen vid. Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Azopt, glejte navodilo za uporabo.
What is Azopt?
Kaj je zdravilo Azopt?
How has Azopt been studied?
Kako je bilo zdravilo Azopt raziskano?
When used as an add-on to travoprost, Azopt had a similar effect to timolol in reducing eye pressure.
Kot dodatek travoprostu je imelo zdravilo Azopt pri zniževanju tlaka v očesu podoben učinek kot timolol.
What is Azopt used for?
Za kaj se zdravilo Azopt uporablja?
How is Azopt used?
Kako se zdravilo Azopt uporablja?
The dose of Azopt is one drop into the affected eye(s) twice a day.
Odmerek zdravila Azopt je ena kapljica v prizadeto oko/prizadeti očesi dvakrat na dan. Nekateri bolniki se bolje odzivajo na odmerek ene kapljice trikrat na dan. Suspenzijo je treba pred uporabo pretresti.
How does Azopt work?
Kako zdravilo Azopt deluje?
- if you are over 65.
- če ste starejši od 65 let.
** based on historical comparison.
** Na osnovi predhodnih primerjav.
As of week 144:
144. teden:
(mechanism)
(mehanizem)
*lower than recommended dose
* nižji od priporočenih odmerkov
in the evening without efavirenz.
zvečer brez efavirenza.
See leaflet for further information.
Glejte navodilo za nadaljnje informacije.
This is very important because the amount of virus may start to increase if the medicine is stopped for even a short time.
To je zelo pomembno, saj se količina virusa lahko začne večati, tudi če zdravilo prenehate jemati samo za kratek čas.
- if any member of your family (parents, grandparents, brothers or sisters) has died suddenly due to a heart problem or was born with heart problems.
če je kateri koli član vaše družine (starši, stari starši, bratje ali sestre) nenadoma umrl zaradi težav s srcem ali je bil rojen s težavami srca,
Interaction studies with these agents have only been performed in adults.
Študije medsebojnega delovanja teh učinkovin so opravili samo pri odraslih.
Detailed information on this medicine is available on the European Medicines Agency web site: http://www.ema.europa.eu
Podrobne informacije o tem zdravilu so objavljene na spletni strani Evropske agencije za zdravila http://www.ema.europa.eu.
Keep the tablet bottle with you so that you can easily describe what you have taken.
Plastenko s tabletami imejte pri sebi, da lahko hitro razložite, kaj ste vzeli.
Tell your doctor immediately if you are pregnant or intend to become pregnant.
Takoj povejte zdravniku, če ste noseči ali načrtujete zanositev.
Values for Test and Reference are mean (% coefficient of variation).
Vrednosti za test in referenco so srednje vrednosti (odstotek koeficienta variabilnosti).
Any inflammatory symptoms should be evaluated and treatment instituted when necessary.
Kakršne koli vnetne simptome je treba oceniti in po potrebi uvesti zdravljenje.
Tenofovir concentrations not measured, no effect is expected.
Koncentracij tenofovirja niso merili, učinki niso pričakovani.
The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c (7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.
Zahteve glede predložitve rednega posodobljenega poročila o varnosti zdravila za to zdravilo so določene v seznamu referenčnih datumov EU (seznamu EURD), opredeljenem v členu 107c(7) Direktive 2001/83/ES, in vseh kasnejših posodobitvah, objavljenih na evropskem spletnem portalu o zdravilih.
The incidence of erythema multiforme or Stevens-Johnson syndrome was approximately 0.1%.
Pojavnost multiformnega eritema ali Stevens-Johnsonovega sindroma je bila približno 0,1-odstotna.
This decrease in atazanavir Cmin might negatively impact the efficacy of atazanavir.
To zmanjšanje atazanavirja Cmin lahko negativno vpliva na učinkovitost atazanavirja.
Table 3: Development of resistance in study GS-01-934 through week 144
Tabela 3: Razvoj odpornosti v študiji GS-01-934 do 144. tedna
Use within 60 days after first opening.
Porabite v 60 dneh po odprtju.
Similar results were found by other investigators, although the MPA plasma levels were more variable in the second study.
Do podobnih rezultatov so prišli tudi drugi raziskovalci, čeprav so bile koncentracije MPA v plazmi v drugi študiji bolj spremenljive.
- if you have severe liver disease.
- če imate hudo jetrno bolezen,
Tell your doctor immediately about new or unusual symptoms after you stop treatment, particularly symptoms you associate with hepatitis B infection.
Zdravnika takoj obvestite o kakršnih koli novih ali nenavadnih simptomih po prenehanju zdravljenja, zlasti o simptomih, ki jih povezujete z okužbo z virusom hepatitisa B.
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 05 September 2017
Datum prve odobritve: 05 September 2017
HORMONAL CONTRACEPTIVES Oral:
HORMONSKA KONTRACEPCIJSKA SREDSTVA Peroralno:
You can also report side effects directly via the national reporting system listed in Appendix V By reporting side effects you can help provide more information on the safety of this medicine.
O neželenih učinkih lahko poročate tudi neposredno na nacionalni center za poročanje, ki je naveden v Prilogi V. S tem, ko poročate o neželenih učinkih, lahko prispevate k zagotovitvi več informacij o varnosti tega zdravila.
Based on the different elimination pathways, no interaction is expected.
Glede na različne poti izločanja medsebojno delovanje ni pričakovano.
*lower than recommended doses; similar findings are expected with recommended doses.
* nižji od priporočenih odmerkov, podobno se pričakuje pri priporočenih odmerkih.
- if you have or have had kidney disease, or if tests have shown problems with your kidneys.
- če imate ali ste imeli bolezen ledvic ali če so testi pokazali, da imate bolezni ledvic.
[To appear on outer carton only]
[Navesti samo na zunanji ovojnini]
Write the date the bottle was opened on the label and/or carton in the space provided.
Napišite datum odprtja plastenke na nalepko in/ali škatlo, v za to predviden prostor.
- if you have a history of mental illness, including depression, or of substance or alcohol abuse.
- če ste kdaj imeli duševne bolezni, vključno z depresijo ali zlorabo alkohola in drugih substanc.
Mean percent change in AUC, Cmax, Cmin with 90% confidence intervals if available
Povprečna sprememba odstotka pričakovane izpostavljenosti (AUC), Cmax, Cmin z 90-odstotnimi intervali zaupanja, če so na voljo
The incidence of neural tube defects in the general population ranges from 0.5-1 case per 1,000 live births.
Pojavnost okvar nevralne cevi pri prebivalstvu na splošno je od 0,5 do 1 primera na 1000 živorojenih otrok.
It is important to tell your doctor or pharmacist if you are taking any of the following:
Pomembno je, da zdravniku ali farmacevtu poveste, če jemljete katero koli izmed naslednjih zdravil:
Do not use this medicine after the expiry date which is stated on the bottle and carton after ‘EXP'.
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na plastenki in škatli poleg oznake „EXP“.
Substitutions at RT positions 98, 100, 101, 108, 138, 188, 190 or 225 were also observed, but at lower frequencies, and often only in combination with K103N.
Opazili so tudi substitucije pri RT na položajih 98, 100, 101, 108, 138, 188, 190 ali 225, vendar redkeje in pogosto le v kombinaciji s K103N.
Lopinavir concentrations: ↓ 30
Koncentracije lopinavirja: ↓ 30
Open date:
Datum odprtja:
Tell your doctor if you are taking other medicines which may damage your kidneys.
Obvestite zdravnika, če jemljete druga zdravila, ki lahko škodijo ledvicam.
<for carton only> Open date:
<samo za škatlo> Datum odprtja:
- if you have a history of liver disease, including chronic active hepatitis.
- če ste v preteklosti imeli bolezen jeter, vključno s kroničnim aktivnim hepatitisom.
A risk to the infants cannot be excluded.
Tveganja za dojenega novorojenčka/otroka ne moremo izključiti.
Frequencies are defined as very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100) or rare (≥ 1/10,000 to < 1/1,000).
Pogostnost je opredeljena kot: zelo pogosti (≥ 1/10), pogosti (≥ 1/100 do < 1/10), občasni (≥ 1/1.000 do < 1/100) ali redki (≥ 1/10.000 do < 1/1.000).
No effect (↔) equals a decrease in mean ratio estimate of ≤ 20% or increase in mean ratio estimate of ≤ 25%.
Brez učinka (↔) je enako zmanjšanju ocene razmerja srednje vrednosti ≤ 20 % ali zvišanju ocene razmerja srednje vrednosti ≤ 25 %.
See ritonavir row below.
Glejte vrstico o ritonavirju spodaj.
- any signs of skin rash.
- kakršne koli znake kožnega izpuščaja.
These metabolites are essentially inactive against HIV-1.
Ti presnovki so večinoma neaktivni proti virusu HIV1.
Confirmatory testing by a more specific method such as gas chromatography/mass spectrometry is recommended in such cases.
V teh primerih je priporočeno izvesti potrjevalne preskuse z bolj specifično metodo, kot je plinska kromatografija/masna spektrometrija.
Some patients accidentally taking 600 mg efavirenz twice daily have reported increased nervous system symptoms.
Nekateri bolniki, ki so pomotoma vzeli 600 mg efavirenza dvakrat na dan, so poročali o povečanju simptomov živčevja.
Efavirenz is an NNRTI of HIV-1.
Efavirenz je NNRTI za HIV-1.
hepatic steatosis, hepatitis
jetrna steatoza, hepatitis
Interaction not studied.
Medsebojnega delovanja niso preučevali.
These tumours are unlikely to be of relevance to humans.
Ni verjetno, da bi bili ti tumorji pomembni za človeka.
- Lactic acidosis (excess lactic acid in the blood) is a rare (may affect up to 1 in every 1,000 patients) but serious side effect that can be fatal.
- Laktacidoza (čezmerna količina mlečne kisline v krvi) je redek (pojavi se lahko pri največ 1 od 1.000 bolnikov), vendar resen neželeni učinek, ki je lahko smrten.
Patients should be instructed that if they experience these symptoms they should avoid potentially hazardous tasks such as driving and operating machinery.
Bolnike je treba poučiti, naj se v primeru teh simptomov izogibajo potencialno nevarnim opravilom, kakršna sta vožnja ali upravljanje strojev.
Expected: Voxilaprevir:↓
Pričakovano: voksilaprevir:↓
- if your doctor has told you that you have high or low levels of electrolytes such as potassium or magnesium in your blood.
če vam je zdravnik povedal, da imate v krvi visok ali nizek nivo elektrolitov, kot sta kalij ali magnezij,
In case of concomitant antiviral therapy for hepatitis B or C, please refer also to the relevant Summary of Product Characteristics for these medicinal products.
V primeru sočasnega protivirusnega zdravljenja hepatitisa B ali C glejte tudi ustrezne Povzetke glavnih značilnosti teh zdravil.
However, as would be expected in this patient population, elevations in AST and ALT occurred more frequently than in the general HIV infected population.
Vendar so se po pričakovanju zvišanja AST in ALT pri tej skupini bolnikov pojavila pogosteje kot pri splošni populaciji bolnikov, okuženih z virusom HIV.
Pharmacotherapeutic group: Antiviral for systemic use, antivirals for treatment of HIV infections, combinations, ATC code: J05AR06.
Farmakoterapevtska skupina: zdravila za sistemsko zdravljenje virusnih infekcij, protivirusna zdravila za zdravljenje infekcij s HIV, kombinacije, oznaka ATC: J05AR06.
Stayed on original treatment regimen (N=97) n/N (%)
Bolniki, ki so ostali na prvotnem zdravljenju (N = 97) n/N (%)
Refer to the Summary of Product Characteristics for the medicinal product containing maraviroc.
Glejte Povzetke glavnih značilnosti zdravila, ki vsebuje maravirok.
Cross-resistance profiles for efavirenz, nevirapine and delavirdine in vitro demonstrated that the K103N substitution confers loss of susceptibility to all three NNRTIs.
Profili navzkrižne odpornosti na efavirenz, nevirapin in delavirdin in vitro so pokazali, da substitucija K103N povzroči izgubo občutljivosti za vse tri NNRTI.
As a general rule, it is recommended that HIV infected women do not breast-feed their infants in order to avoid transmission of HIV to the infant.
Na splošno je priporočljivo, da ženske, okužene z virusom HIV, ne dojijo, da se prepreči prenos virusa HIV na dojenčka.
As neural tube defects occur within the first 4 weeks of foetal development (at which time neural tubes are sealed), this potential risk would concern women exposed to efavirenz during the first trimester of pregnancy.
Ker do okvar nevralne cevi pride samo v prvih 4 tednih razvoja plodu (ko se nevralne cevi zaprejo), bi to potencialno tveganje zadevalo ženske, izpostavljene efavirenzu v prvem trimesečju nosečnosti.
In children whose mothers took NRTIs during pregnancy, the benefit from the protection against HIV outweighed the risk of side effects.
Pri otrocih, katerih matere so med nosečnostjo jemale nukleozidne zaviralce reverzne transkriptaze (NRTI), je korist zaščite pred virusom HIV odtehtala tveganje za neželene učinke.
Both the K65R and M184V/I mutation remain fully susceptible to efavirenz.
Tako mutacija K65R kot M184V/I pa ostajata popolnoma občutljivi za efavirenz.
Patients should be advised to seek medical advice if they experience joint aches and pain, joint stiffness or difficulty in movement.
Bolnikom je treba svetovati, naj poiščejo zdravniško pomoč, če se pojavijo bolečine v sklepih, togost sklepov ali težave pri gibanju.
Tenofovir is primarily excreted by the kidneys by both filtration and an active tubular transport system with approximately 70 to 80% of the dose excreted unchanged in urine following intravenous administration.
Tenofovir se primarno izloča skozi ledvici tako z glomerulno filtracijo kot z aktivnim tubularnim transportnim sistemom, pri čemer se po intravenskem vnosu približno 70 do 80 % odmerka izloči nespremenjenega z urinom.
The oral bioavailability of tenofovir from tenofovir disoproxil in fasted patients was approximately 25%.
Peroralna biološka uporabnost tenofovirja iz dizoproksiltenofovirata pri teščih bolnikih je bila približno 25 %.
One tablet taken each day by mouth.
Priporočeni odmerek je: ena tableta na dan, ki jo zaužijete skozi usta.
The clinical outcome of this observed reduction of boceprevir trough concentrations has not been directly assessed.
Klinični izid tega opazovanega zmanjšanja najmanjše koncentracije boceprevira še ni bil neposredno ovrednoten.
117 Allée Des Parcs, 69 800 Saint-Priest, France
117 Allée Des Parcs, 69 800 Saint-Priest, Francija
- Independent of a history of liver disease, your doctor will consider regular blood tests to check how your liver is working.
- Neodvisno od tega, ali ste prej kdaj imeli jetrno bolezen, bo vaš zdravnik razmislil o rednih krvnih preiskavah, da preveri, kako delujejo vaša jetra.
Verapamil, Felodipine, Nifedipine and Nicardipine
Verapamil, felodipin, nifedipin in nikardipin
It is not considered to be causally associated with tenofovir disoproxil in the absence of this condition.
Ne obravnava se, kot da je vzročno povezana s dizoproksiltenofoviratom v odsotnosti tega stanja.
abnormal dreams, insomnia
nenormalne sanje, nespečnost
There were insufficient data to determine whether moderate or severe hepatic impairment (Child-Pugh-Turcotte Class B or C) affects efavirenz pharmacokinetics.
Ni bilo dovolj podatkov, da bi ugotovili, ali zmerna ali huda jetrna okvara (razreda B ali C po Child- PughTurcotteovi lestvici) vpliva na farmakokinetiko efavirenza.
These problems tend to occur more often in those who have a history of mental illness.
Te težave se pogosteje pojavijo pri bolnikih, ki so v preteklosti imeli duševno bolezen.
Patients should be advised that if they experience symptoms such as severe depression, psychosis or suicidal ideation, they should contact their doctor immediately to assess the possibility that the symptoms may be related to the use of efavirenz, and if so, to determine whether the risk of continued therapy outweighs the benefits (see section 4.8).
Bolnikom je treba svetovati, naj se v primeru pojava simptomov, kot so huda oblika depresije, psihoza ali misel na samomor, nemudoma posvetujejo s svojim zdravnikom, ki bo ocenil, ali so simptomi povezani z jemanjem efavirenza, in če je tako, odločil, ali je tveganje nadaljevanja zdravljenja z efavirenzom večje od koristi (glejte poglavje 4.8).
In other studies (prospective and cross-sectional), the most pronounced decreases in BMD were seen in patients treated with tenofovir disoproxil as part of a regimen containing a boosted protease inhibitor.
V drugih študijah (prospektivne in presečne) so najbolj izrazito zmanjšanje MGK opazili pri bolnikih, zdravljenih z dizoproksiltenofoviratom kot delom režima, ki je vseboval okrepljenega zaviralca proteaze.
• itchy rash to the skin caused by a reaction to sunlight
• srbeč kožni izpuščaj, ki ga povzroči reakcija na sončno svetlobo.
This medicine is available in plastic bottles containing a desiccant labelled ‘DO NOT EAT' and 30 tablets and in multipacks of 90 tablets comprising 3 bottles, each containing 30 tablets.
To zdravilo je na voljo v plastenkah s sušilnim sredstvom z oznako „DO NOT EAT“, ki vsebujejo 30 filmsko obloženih tablet in v skupnih pakiranjih z 90 filmsko obloženimi tabletami, ki vsebujejo 3 plastenke s 30 filmsko obloženimi tabletami.
Dihydroartemisinin (active metabolite):
Dihidroartemizinin (aktivni presnovek):
It contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially ‘sodium-free'.
To zdravilo vsebuje manj kot 1 mmol (23 mg) natrija na odmerek, kar v bistvu pomeni ‘'brez natrija''.
Rare completed suicide3,4, delusion3,4, neurosis3,4
Redki storjen samomor3,4, deluzija3,4, nevroza3,4
If you notice any symptoms of infection or other symptoms such as muscle weakness, weakness beginning in the hands and feet and moving up towards the trunk of the body, palpitations, tremor or hyperactivity, please inform your doctor immediately to seek necessary treatment.
Če opazite kakršne koli simptome okužbe ali druge simptome, na primer mišično oslabelost, oslabelost, ki se najprej pojavi v dlaneh in stopalih in nato širi proti trupu, palpitacije, tremor ali hiperaktivnost, zaradi potrebnega zdravljenja nemudoma obvestite zdravnika.
- signs of dizziness, difficulty sleeping, drowsiness, difficulty concentrating or abnormal dreaming.
- znake omotice, težave pri spanju, zaspanost, težave s koncentracijo ali nenormalne sanje.
Most cases occurred in patients who already had liver disease, but there have been a few reports in patients without any existing liver disease
Ta učinek se je pojavil večinoma pri bolnikih, ki so že imeli jetrno bolezen, vendar pa je bilo nekaj poročanj o pojavu pri bolnikih, ki prej niso imeli jetrne bolezni;
Skin and subcutaneous tissue disorders: Very common rash (moderate-severe, 11.6%, all grades, 18%)3
Bolezni kože in podkožja: Zelo pogosti izpuščaj (zmeren-hud, 11,6 %, vse stopnje, 18 %)3